GATA binding protein 5-mediated transcriptional activation of transmembrane protein 100 suppresses cell proliferation, migration and epithelial-to-mesenchymal transition in prostate cancer DU145 cells.


Journal

Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063

Informations de publication

Date de publication:
04 2022
Historique:
entrez: 31 3 2022
pubmed: 1 4 2022
medline: 9 4 2022
Statut: ppublish

Résumé

It has been reported that transmembrane protein 100 (TMEM100) acts as a tumor regulator in several types of cancers. However, whether the expression of TMEM100 is associated with the development and prognosis of prostate cancer (PCa) remains elusive. Therefore, the present study aimed to uncover the role of GATA binding protein 5 (GATA5)-mediated activation of TMEM100 in the proliferation, migration and epithelial-to-mesenchymal transition (EMT) of PCa cells. The expressions of TMEM100 and GATA5 in PCa patients were analyzed by the GEPIA database. The binding site of GATA5 and TMEM100 promoter was predicted by the JASPAR database. Expressions of TMEM100 and GATA5 in PCa cells were detected by qRT-PCR and Western blot analysis. Cell Counting Kit 8 and colony formation assays were performed to measure cell proliferation. In addition, cell migration, invasion and the expression of EMT-associated proteins were evaluated using wound healing, transwell assay and Western blotting assays, respectively. The bioinformatics analysis revealed that TMEM100 was downregulated in PCa and was associated with overall survival of PCa. In addition, TMEM10 overexpression attenuated cell proliferation, migration, invasion and EMT in PCa cells. The interaction between TMEM100 and GATA5 was verified using dual luciferase reporter and chromatin immunoprecipitation assays. Furthermore, the results showed that GATA5 was downregulated and GATA5 silencing reversed the inhibitory effects of TMEM10 on PCa cells. Overall, the current study suggested that the GATA5-mediated transcriptional activation of TMEM100 could affect the behavior of PCa cells and was associated with poor prognosis in PCa.

Identifiants

pubmed: 35358005
doi: 10.1080/21655979.2021.2018979
pmc: PMC9162018
doi:

Substances chimiques

GATA5 Transcription Factor 0
Membrane Proteins 0
TMEM100 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7972-7983

Références

Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Genes Cancer. 2010 Dec;1(12):1178-88
pubmed: 21779441
Asian Pac J Cancer Prev. 2014;15(22):9575-8
pubmed: 25520069
Cell Prolif. 2019 May;52(3):e12576
pubmed: 30719778
Hum Mol Genet. 2012 Feb 1;21(3):711-20
pubmed: 22021425
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Angiogenesis. 2020 Aug;23(3):339-355
pubmed: 32112176
Cancer Cell Int. 2019 Dec 03;19:327
pubmed: 31827401
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Surg. 2021 Oct 14;8:644057
pubmed: 34722618
J Clin Invest. 2017 Sep 1;127(9):3527-3542
pubmed: 28758902
Oncol Rep. 2021 May;45(5):
pubmed: 34184748
Cell Rep. 2012 Nov 29;2(5):1197-206
pubmed: 23142663
Expert Rev Clin Pharmacol. 2018 Apr;11(4):425-438
pubmed: 29355037
Oncotarget. 2015 Jul 10;6(19):17379-90
pubmed: 25978032
BJU Int. 2019 Jul;124(1):1
pubmed: 31206999
Neuron. 2015 Feb 18;85(4):833-46
pubmed: 25640077
BJU Int. 2006 Oct;98(4):886-97
pubmed: 16978289
Am J Transl Res. 2017 May 15;9(5):2567-2578
pubmed: 28560005
Mol Cancer. 2017 Jul 10;16(1):117
pubmed: 28693582
Bioengineered. 2021 Dec;12(1):9094-9102
pubmed: 34654353
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92
pubmed: 31701148
Mol Cell Biol. 2003 Dec;23(23):8429-39
pubmed: 14612389
Int J Urol. 2018 May;25(5):390-403
pubmed: 29572963
Biol Chem. 2020 Feb 25;401(2):285-296
pubmed: 31188741
Oncol Lett. 2016 Jan;11(1):861-869
pubmed: 26870297
PLoS One. 2021 Mar 8;16(3):e0248203
pubmed: 33684162
World J Gastroenterol. 2015 Mar 7;21(9):2629-37
pubmed: 25759530
Prostate. 2015 Jun 15;75(9):907-16
pubmed: 25728608
J Cell Mol Med. 2019 Jan;23(1):29-38
pubmed: 30565858
Support Care Cancer. 2020 Oct;28(10):4813-4824
pubmed: 31980895
J Med Life. 2017 Jan-Mar;10(1):5-12
pubmed: 28255369
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Oncol Rep. 2021 Aug;46(2):
pubmed: 34278505
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12064-9
pubmed: 22783020
Nat Rev Urol. 2021 Mar;18(3):170-184
pubmed: 33637962
Transl Oncol. 2018 Jun;11(3):585-592
pubmed: 29547757
Genesis. 2010 Nov;48(11):673-8
pubmed: 20848592
Poult Sci. 2021 Feb;100(2):844-857
pubmed: 33518138
Cancer. 2016 Apr 1;122(7):1000-8
pubmed: 26848808
Cancer Biol Med. 2021 Mar 12;:
pubmed: 33710810

Auteurs

Jiaolin Liu (J)

Department of Urology, The Central Hospital of Linyi, Linyi, Shandong, China.

Fanlu Lin (F)

Department of Urology, The Central Hospital of Linyi, Linyi, Shandong, China.

Xin Wang (X)

Department of Urology, Linyi People's Hospital, Linyi, Shandong, China.

Chaopeng Li (C)

Department of Urology, The Central Hospital of Linyi, Linyi, Shandong, China.

Qiangyuan Qi (Q)

Department of Urology, The Central Hospital of Linyi, Linyi, Shandong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH